Global, multicenter, randomized, open-label, parallel-group study will evaluate ABBV-383 in adult patients with relapsed/refractory multiple myeloma.
AbbVie has announced that the first patient has been treated with its investigational ABBV-383 in the CERVINO Phase III study (NCT06158841). The trial is a global, multicenter, randomized, open-label, parallel-group study evaluating the investigational therapy in adult patients with relapsed/refractory multiple myeloma who received at least two lines of prior therapy.1
According to AbbVie, ABBV-383 is a distinctive B-cell maturation antigen (BCMA) and CD3 bispecific antibody T-cell engager composed of bivalent BCMA-binding domains allowing for high BCMA-avidity and a low-affinity CD3 binding domain.
"Despite notable advances in treatment, most patients with multiple myeloma will eventually relapse. Patients with advanced disease, especially in the community setting, often have limited access to novel treatment options and existing options have a high treatment burden, including frequent dosing," Peter Voorhees, MD, clinical professor of medicine, director of plasma cell disorders, Atrium Health Levine Cancer Institute said in a press release "The CERVINO Phase III trial is designed to evaluate the efficacy of ABBV-383 with monthly dosing and we look forward to seeing the data as it emerges."
The dual primary end points for the study are progression-free survival and overall response rate. Secondary end points include overall survival, complete response (CR) or better, very good partial response or better, rate of minimum residual disease negativity, and change in disease symptoms and physical functioning. Approximately 140 sites are expected to enroll approximately 380 total patients.
In 2024, an estimated 35,780 cases of multiple myeloma will be diagnosed (19,520 in men and 16,260 in women).2
"The start of the CERVINO Phase III trial marks an important step forward in AbbVie's continued commitment to advance new oncology treatments and elevate the standard of care for blood cancer patients," Mariana Cota Stirner, MD, PhD, vice president, therapeutic area head oncology, hematology, AbbVie said in the press release. "ABBV-383 is being evaluated with monthly dosing from the beginning of treatment, with the goal of maximizing treatment simplicity for physicians and patients, if proven in the clinical trials."
1. AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383. News release. June 5, 2024. Accessed June 7, 2024. https://www.prnewswire.com/news-releases/abbvie-advances-oncology-pipeline-with-start-of-multiple-myeloma-phase-3-clinical-trial-for-investigational-asset-abbv-383-302164808.html
2. Key Statistics About Multiple Myeloma. American Cancer Society. Updated January 19, 2024. Accessed June 7, 2024. https://www.cancer.org/cancer/types/multiple-myeloma/about/key-statistics.html
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.